Generex Biotechnology Corporatio (GNBT) 0.0185 $GNBT
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment
PR Newswire - Thu May 14, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today that updated data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine under development at the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). The current analysis was performed on data that was examined one year after the last patient was enrolled into the trial. The ASCO meeting will be held from May 29 to June 2, 2015 in Chicago, IL.
Is Generex Now A Cannabis Play?
Nick Cox - at Seeking Alpha - Tue May 05, 3:52PM CDT
Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split
PR Newswire - Mon May 04, 8:30AM CDT
Dividend to occur after completion of reverse stock split, definitive licensing agreement, and effective registration of SMFI securities
Penny Stocks Buzz for Valmie Resources, Breathe Ecig, Elite Data Services, CANNAGROW, Revolutionary Concepts, and Generex Biotechnology
PR Newswire - Fri Apr 24, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), Breathe Ecig (OTCMKTS:BVAP), Elite Data Services (OTCBB
EAC), CANNAGROW (OTCMKTS:CGRW), Revolutionary Concepts (OTCMKTS:REVO), and Generex Biotechnology (OTCMKTS:GNBT).
Generex Announces New $11 Million Collaboration on Buccal Cannabis
CNW Group - Thu Apr 23, 8:45AM CDT
Generex to receive $10M in common stock, a warrant, & $1M in R&D funding
Generex Announces Presentation of Data Correlating Immune Response with Reduction of Relapse in AE37 Phase II Breast Cancer Trial at AACR 2015
PR Newswire - Tue Apr 21, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today presentation of data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine correlating local immune response to a reduction in relapse. AE37 is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex. The presentation was made at the American Association for Cancer Research (AACR) Annual Meeting held in Philadelphia, PA from April 18 to 22.
Generex Acknowledges the Contributions of Its Chairman
CNW Group - Tue Apr 07, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the resignation of John P. Barratt as a member of the Company's Board of Directors. For medical reasons, Mr. Barratt has made the decision to take full retirement from his myriad corporate responsibilities. The resignation from the Generex Board of Directors will take effect on April 30, 2015.
Generex successful in increasing insulin concentration in spray product candidate
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 10:44AM CDT
MNKD: 4.22 (+0.23)
Generex Provides Update on Buccal Insulin Formulation Enhancement Project
PR Newswire - Thu Mar 12, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today provided an update on the status of the buccal insulin formulation enhancement project for the Company's proprietary Generex Oral-lyn(TM) buccal insulin spray product. As previously announced, Generex has engaged the Center for Molecular Design and Preformulations (CMDP) (cmdp.uhnres.utoronto.ca) at University Health Network (www.uhn.ca) with the goal of enhancing the Generex Oral-lyn(TM) formulation to make it more attractive to patients and prospective commercialization partners by increasing the bioavailability of insulin in the product and reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. The project has moved forward under the supervision of Dr. David Brusegard, Ph.D., the Company's Chief Operating Officer, Dr. James H. Anderson, Jr., MD, the Company's Senior Scientific Advisor, and Generex consultant Dr. Lakshmi P. Kotra, B. Pharm.(Hons), Ph.D.
Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
CNW Group - Tue Feb 17, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that results of the last pre-specified analysis of data from a Phase II study of a novel cancer vaccine designed to reduce the risk of relapse in patients who have had breast cancer corroborate qualitatively prior results from the primary analysis conducted in January of 2014. The Company plans to disclose the latest results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 29 to June 2, 2015. The ASCO Annual Meeting is the premier annual oncology symposium, bringing together more than 25,000 oncology professionals from a broad range of specialties. An abstract in respect of the results of the Phase II trial has been submitted to the ASCO Annual Meeting; per ASCO rules, the contents of those abstracts are embargoed pending the meeting.
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 48.87 (+0.16), MDT: 76.82 (+0.40), LXRX: 1.00 (-0.01), AMGN: 161.83 (-0.53), LLY: 72.81 (-0.09), GSK: 44.75 (-0.02), ECTE: 1.29 (-0.04), JNJ: 102.92 (+0.62), NVO: 56.83 (+0.08), AZN: 68.91 (-0.38), MRK: 60.27 (+0.04), NVS: 104.07 (+0.32)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 22.54 (-0.48), ADMP: 3.90 (-0.38)
Generex Announces Participation in MedCannAccess® - CannScience Partnership on Non-Smoked Forms of Marijuana
PR Newswire - Wed Dec 17, 8:00AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced its participation in a MedCannAccess (www.MedCannAccess.com) partnership with CannScience Innovations Inc.
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment
PR Newswire - Thu May 14, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today that updated data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine under development at the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). The current analysis was performed on data that was examined one year after the last patient was enrolled into the trial. The ASCO meeting will be held from May 29 to June 2, 2015 in Chicago, IL.
Is Generex Now A Cannabis Play?
Nick Cox - at Seeking Alpha - Tue May 05, 3:52PM CDT
Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split
PR Newswire - Mon May 04, 8:30AM CDT
Dividend to occur after completion of reverse stock split, definitive licensing agreement, and effective registration of SMFI securities
Penny Stocks Buzz for Valmie Resources, Breathe Ecig, Elite Data Services, CANNAGROW, Revolutionary Concepts, and Generex Biotechnology
PR Newswire - Fri Apr 24, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), Breathe Ecig (OTCMKTS:BVAP), Elite Data Services (OTCBB
EAC), CANNAGROW (OTCMKTS:CGRW), Revolutionary Concepts (OTCMKTS:REVO), and Generex Biotechnology (OTCMKTS:GNBT). Generex Announces New $11 Million Collaboration on Buccal Cannabis
CNW Group - Thu Apr 23, 8:45AM CDT
Generex to receive $10M in common stock, a warrant, & $1M in R&D funding
Generex Announces Presentation of Data Correlating Immune Response with Reduction of Relapse in AE37 Phase II Breast Cancer Trial at AACR 2015
PR Newswire - Tue Apr 21, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today presentation of data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine correlating local immune response to a reduction in relapse. AE37 is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex. The presentation was made at the American Association for Cancer Research (AACR) Annual Meeting held in Philadelphia, PA from April 18 to 22.
Generex Acknowledges the Contributions of Its Chairman
CNW Group - Tue Apr 07, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the resignation of John P. Barratt as a member of the Company's Board of Directors. For medical reasons, Mr. Barratt has made the decision to take full retirement from his myriad corporate responsibilities. The resignation from the Generex Board of Directors will take effect on April 30, 2015.
Generex successful in increasing insulin concentration in spray product candidate
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 10:44AM CDT
MNKD: 4.22 (+0.23)
Generex Provides Update on Buccal Insulin Formulation Enhancement Project
PR Newswire - Thu Mar 12, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today provided an update on the status of the buccal insulin formulation enhancement project for the Company's proprietary Generex Oral-lyn(TM) buccal insulin spray product. As previously announced, Generex has engaged the Center for Molecular Design and Preformulations (CMDP) (cmdp.uhnres.utoronto.ca) at University Health Network (www.uhn.ca) with the goal of enhancing the Generex Oral-lyn(TM) formulation to make it more attractive to patients and prospective commercialization partners by increasing the bioavailability of insulin in the product and reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. The project has moved forward under the supervision of Dr. David Brusegard, Ph.D., the Company's Chief Operating Officer, Dr. James H. Anderson, Jr., MD, the Company's Senior Scientific Advisor, and Generex consultant Dr. Lakshmi P. Kotra, B. Pharm.(Hons), Ph.D.
Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
CNW Group - Tue Feb 17, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that results of the last pre-specified analysis of data from a Phase II study of a novel cancer vaccine designed to reduce the risk of relapse in patients who have had breast cancer corroborate qualitatively prior results from the primary analysis conducted in January of 2014. The Company plans to disclose the latest results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 29 to June 2, 2015. The ASCO Annual Meeting is the premier annual oncology symposium, bringing together more than 25,000 oncology professionals from a broad range of specialties. An abstract in respect of the results of the Phase II trial has been submitted to the ASCO Annual Meeting; per ASCO rules, the contents of those abstracts are embargoed pending the meeting.
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 48.87 (+0.16), MDT: 76.82 (+0.40), LXRX: 1.00 (-0.01), AMGN: 161.83 (-0.53), LLY: 72.81 (-0.09), GSK: 44.75 (-0.02), ECTE: 1.29 (-0.04), JNJ: 102.92 (+0.62), NVO: 56.83 (+0.08), AZN: 68.91 (-0.38), MRK: 60.27 (+0.04), NVS: 104.07 (+0.32)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 22.54 (-0.48), ADMP: 3.90 (-0.38)
Generex Announces Participation in MedCannAccess® - CannScience Partnership on Non-Smoked Forms of Marijuana
PR Newswire - Wed Dec 17, 8:00AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced its participation in a MedCannAccess (www.MedCannAccess.com) partnership with CannScience Innovations Inc.
